JP2003518484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518484A5 JP2003518484A5 JP2001548088A JP2001548088A JP2003518484A5 JP 2003518484 A5 JP2003518484 A5 JP 2003518484A5 JP 2001548088 A JP2001548088 A JP 2001548088A JP 2001548088 A JP2001548088 A JP 2001548088A JP 2003518484 A5 JP2003518484 A5 JP 2003518484A5
- Authority
- JP
- Japan
- Prior art keywords
- salmeterol
- formulation
- concentration
- formulation according
- fluticasone propionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 18
- 229960004017 salmeterol Drugs 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 10
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 9
- 229960000289 fluticasone propionate Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000008249 pharmaceutical aerosol Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229950000339 Xinafoate Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- GIIZNNXWQWCKIB-VWLOTQADSA-N (R)-salmeterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-VWLOTQADSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical group FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- XTZNCVSCVHTPAI-UHFFFAOYSA-N 2-carboxynaphthalen-1-olate;[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-[6-(4-phenylbutoxy)hexyl]azanium Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 229960005018 Salmeterol xinafoate Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930878.5A GB9930878D0 (en) | 1999-12-24 | 1999-12-24 | Pharmaceutical formulation |
GB9930878.5 | 1999-12-24 | ||
GB0018686A GB0018686D0 (en) | 2000-07-28 | 2000-07-28 | Pharmaceutical formulation |
GB0018686.6 | 2000-07-28 | ||
PCT/GB2000/004939 WO2001047493A1 (en) | 1999-12-24 | 2000-12-21 | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003518484A JP2003518484A (ja) | 2003-06-10 |
JP2003518484A5 true JP2003518484A5 (de) | 2007-12-27 |
Family
ID=26244762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001548088A Pending JP2003518484A (ja) | 1999-12-24 | 2000-12-21 | サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030032632A1 (de) |
EP (1) | EP1248597B1 (de) |
JP (1) | JP2003518484A (de) |
AT (1) | ATE291898T1 (de) |
AU (1) | AU2206801A (de) |
DE (1) | DE60019167T2 (de) |
ES (1) | ES2238334T3 (de) |
WO (1) | WO2001047493A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
US20050048001A1 (en) * | 1999-11-23 | 2005-03-03 | Cripps Alan Leslie | Pharmaceutical formulations of salmeterol |
ATE286716T1 (de) * | 1999-11-23 | 2005-01-15 | Glaxo Group Ltd | Pharmazeutische formulierungen enthaltend salmeterol |
IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
HU230804B1 (hu) | 2000-05-22 | 2018-06-28 | Chiesi Farmaceutici S.P.A | Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
GB2367011A (en) * | 2000-08-26 | 2002-03-27 | Glaxo Group Ltd | Metered dose inhaler for salmeterol |
PE20020387A1 (es) * | 2000-08-31 | 2002-06-24 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
GB0021927D0 (en) * | 2000-09-07 | 2000-10-25 | Glaxo Group Ltd | Use of pharmaceutical combination |
GB0105560D0 (en) * | 2001-03-07 | 2001-04-25 | Glaxo Group Ltd | Pharmaceutical formulations |
GB0106031D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Use |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
EP1415647A1 (de) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | Langwirkende beta-2-Agonisten in ultrafeiner Formulierung |
AU2003265639A1 (en) * | 2002-08-27 | 2004-03-19 | Schering Corporation | Process for producing metered dose inhaler formulations |
ES2317306T3 (es) * | 2004-10-12 | 2009-04-16 | Generics (Uk) Limited | Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol. |
US7680778B2 (en) * | 2007-01-19 | 2010-03-16 | Microsoft Corporation | Support for reverse and stemmed hit-highlighting |
GB0712454D0 (en) * | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
EP2571486A4 (de) * | 2010-05-20 | 2013-12-04 | Sun Pharma Advanced Res Co Ltd | Trockenpulverinhalationszusammensetzung |
TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
MY171271A (en) | 2011-08-19 | 2019-10-07 | Intech Biopharm Ltd | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
CN102379846B (zh) * | 2011-10-21 | 2014-07-02 | 江苏长风药业有限公司 | 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂 |
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
EP2847207B1 (de) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Nanokristalle von Fluticasonpropionat |
US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
MX2016017038A (es) * | 2014-06-25 | 2017-05-01 | Optinose As | Administracion nasal. |
EP3174522A1 (de) | 2014-07-29 | 2017-06-07 | 3M Innovative Properties Company | Verfahren zur herstellung einer pharmazeutischen zusammensetzung |
CN113288869A (zh) | 2016-09-19 | 2021-08-24 | 墨西哥氟石股份公司 | 药物组合物 |
CN109715148A (zh) | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
CN114515284A (zh) | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE629985A (de) * | 1962-11-29 | |||
CH634480A5 (de) * | 1977-11-25 | 1983-02-15 | Schwarzkopf Gmbh Hans | Unter druck stehendes aerosolpraeparat. |
IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
US5919827A (en) * | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
CA2094266C (en) * | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
MX9203481A (es) * | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
WO1994013263A1 (en) * | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
CA2273835A1 (en) * | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
WO1998034595A1 (de) * | 1997-02-05 | 1998-08-13 | Jago Research Ag | Medizinische aerosolformulierungen |
GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
GB2332372B (en) * | 1997-12-08 | 2002-08-14 | Minnesota Mining & Mfg | Pharmaceutical aerosol compositions |
GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
EP1087750B1 (de) * | 1998-06-18 | 2003-11-12 | Boehringer Ingelheim Pharmaceuticals Inc. | Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US6231519B1 (en) * | 1999-05-04 | 2001-05-15 | Nokia Corporation | Method and apparatus for providing air quality analysis based on human reactions and clustering methods |
US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
EP1143930B8 (de) * | 1999-09-11 | 2008-03-19 | Glaxo Group Limited | Fluticasonpropionat arzneizubereitung |
DE60103976T2 (de) * | 2000-01-31 | 2005-07-21 | Pfizer Products Inc., Groton | Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme |
-
2000
- 2000-12-21 AU AU22068/01A patent/AU2206801A/en not_active Abandoned
- 2000-12-21 WO PCT/GB2000/004939 patent/WO2001047493A1/en active IP Right Grant
- 2000-12-21 DE DE60019167T patent/DE60019167T2/de not_active Expired - Lifetime
- 2000-12-21 US US10/168,672 patent/US20030032632A1/en not_active Abandoned
- 2000-12-21 EP EP00985666A patent/EP1248597B1/de not_active Expired - Lifetime
- 2000-12-21 JP JP2001548088A patent/JP2003518484A/ja active Pending
- 2000-12-21 ES ES00985666T patent/ES2238334T3/es not_active Expired - Lifetime
- 2000-12-21 AT AT00985666T patent/ATE291898T1/de not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003518484A5 (de) | ||
EP0789557B1 (de) | Treibgasmischung für eine aerosolzubereitung | |
JP5392880B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 | |
JP3280974B2 (ja) | 医 薬 | |
JP2786493B2 (ja) | 医薬エアゾール製剤 | |
JP3026841B2 (ja) | 医 薬 | |
JP4794701B2 (ja) | エアゾール製剤 | |
JP3776124B2 (ja) | 少なくとも一種の糖を含んでなる医薬用エアゾール | |
US20150250713A1 (en) | Pharmaceutical Composition | |
JPH10506887A (ja) | 医薬品 | |
SK92494A3 (en) | Pharmaceutical agent | |
CA2477881A1 (en) | Formoterol superfine formulation | |
JPH07509475A (ja) | 医薬 | |
JP2003509359A (ja) | プロピオン酸フルチカゾンの医薬製剤 | |
JP2007503873A (ja) | 医療用定量噴霧式吸入器及びそれに関連する方法 | |
AU2009312598A1 (en) | Pharmaceutical aerosol composition | |
MX2012003303A (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero. | |
AU2008269528B2 (en) | Pharmaceutical aerosol compositions comprising fluticasone | |
US20130160761A1 (en) | Pharmaceutical Aerosol Composition | |
US20110182830A1 (en) | Inhalation drug products, systems and uses | |
WO2007034207A2 (en) | Troventol formulation | |
EP2911649A2 (de) | Pharmazeutische zusammensetzung mit tiotropium und einem hydrofluoroalkan | |
JP2011093915A (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |